While BCR-ABL tyrosine kinase inhibitors are becoming standard care for patients with Philadelphia chromosome positive ALL56, therapeutic resistance in pre-B-ALL is common and is caused by the rapid emergence of the T315I BCR-ABL kinase domain (gatekeeper) mutation32, 56. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.